EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)

Emily Garvey iD, Bita Naimi iD, Alexander Duffy, Paavali Hannikainen, Chase Kahn, Douglas Farquhar, Marc Rosen, Mindy Rabinowitz, Elina Toskala, Gurston Nyquist

International Forum of Allergy & Rhinology · 2024-03 · 14 (3) · 651-659

DOI: 10.1002/alr.23246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 10.08.2023. Verfasst von Emily Garvey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Rhinosinusitis, Sinusitis, Nasal Polyps, Asthma, Aspirin-Induced. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is often treated with endoscopic sinus surgery (ESS); however, patients may require revision surgery due to recurrence. To date, no studies have compared outcomes for combined surgery and biologic therapy for CRSwNP compared with biologic therapy alone.

Methods

Retrospective case–control study of CRSwNP patients who underwent ESS while on dupilumab or mepolizumab (ESS‐biologic cohort) compared with CRSwNP patients on biologic therapy (biologic‐only controls). Cohorts were matched according to indication, aspirin‐exacerbated respiratory disease (AERD), sinonasal outcome test‐22 (SNOT‐22), and total polyp scores.

Results

Sixteen patients underwent ESS while on biologic therapy (13 dupilumab and 3 mepolizumab). Sixteen patients were biologic‐only controls. There were no significant differences between indication, baseline SNOT‐22 scores, polyp scores, and AERD status between cohorts. Patients underwent surgery a median of 33 days after starting biologic therapy. After 12 months of follow‐up, the total polyp score for the ESS‐biologic cohort decreased from 4.73 to 0.09 compared with a decrease from 5.22 to 3.38 for the biologic‐only controls (95% confidence interval [CI] of difference: −5.37 to −1.38, Cohen's d : 2.40, p = 0.005). In the ESS‐dupilumab subanalysis, the ESS‐dupilumab cohort had a significant reduction in polyp burden from 4.85 to 0.00 compared with 4.88 to 3.50 for the controls (95% CI of difference: −5.68 to −1.32, Cohen's d : −1.69, p = 0.009).

Conclusion

In CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared with biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisSinusitisNasal PolypsAsthma, Aspirin-InducedBiological ProductsRhinitisHumansRetrospective StudiesCase-Control StudiesTreatment OutcomeChronic Disease

Stichwörter der Autor:innen

CRSwNPbiologic therapyendoscopic sinus surgery

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Otolaryngology Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
  • Thomas Jefferson Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Emily Garvey, Bita Naimi

Zitieren

APA

Garvey, E., Naimi, B., Duffy, A., Hannikainen, P., Kahn, C., Farquhar, D., Rosen, M., Rabinowitz, M., Toskala, E., & Nyquist, G. (2024). Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). International Forum of Allergy & Rhinology, 14(3), 651-659. https://doi.org/10.1002/alr.23246

Vancouver

Garvey E, Naimi B, Duffy A, Hannikainen P, Kahn C, Farquhar D, et al. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). International Forum of Allergy & Rhinology. 2024;14(3):651-659. doi:10.1002/alr.23246

BibTeX
@article{Garvey2024,
  author = {Garvey, Emily and Naimi, Bita and Duffy, Alexander and Hannikainen, Paavali and Kahn, Chase and Farquhar, Douglas and Rosen, Marc and Rabinowitz, Mindy and Toskala, Elina and Nyquist, Gurston},
  title = {Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  volume = {14},
  number = {3},
  pages = {651--659},
  doi = {10.1002/alr.23246}
}
Kostenlos starten →